Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on April 5, 2011, reporting events occurring on April 4, 2011. The filing addresses significant executive leadership changes within the company's largest operating unit, AmerisourceBergen Drug Corporation (ABDC).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel appointments rather than financial performance data.
Material Changes
- Executive Appointment: David W. Neu, 53, was named President of AmerisourceBergen Drug Corporation (ABDC), effective immediately.
- Internal Promotion: Mr. Neu is a 29-year veteran of the company, previously serving as Senior Vice President, Operations for ABDC.
- Reporting Structure: Mr. Neu will report to Steven Collis, Executive Vice President and Chief Operating Officer.
- CEO Succession Context: The filing notes that Steven Collis was recently named to succeed David Yost as Chief Executive Officer upon Mr. Yost's scheduled retirement on July 1, 2011.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on market conditions, or discussion of risks and contingencies. The document serves solely to disclose the personnel change and incorporates the related news release as Exhibit 99.1.
Key Facts for Investor Verification
- Confirm the effective date of David W. Neu's appointment as President of ABDC (April 4, 2011).
- Verify the timeline for David Yost's retirement and Steven Collis's assumption of the CEO role (July 1, 2011).
- Review the full text of the news release filed as Exhibit 99.1 for additional details on the leadership transition.